Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase i studies

British Journal of Cancer

Volumn 107, Issue 4, 2012, Pages 612-616

  Mandala M ^a   Grosso, F ^b   Vitalini, C ^c   Corradino, I ^c   Sanfilippo, R ^d   Colombini, S ^c   Clerici, M ^c   Labianca, R ^a   De Pascale, A ^c   Marsoni, S ^c  

^a OSPEDALI RIUNITI   (Italy)

^b C Arrigo Children's Hospital   (Italy)

^c SENDO Foundation   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

adverse event; phase I studies; venous thromboembolism

Indexed keywords

ANGIOGENESIS INHIBITOR; CYTOTOXIC AGENT; HEMOGLOBIN;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DRUG ERUPTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TUMOR; GYNECOLOGIC CANCER; HUMAN; INFECTION; LEUKOCYTE COUNT; LIVER FUNCTION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SARCOMA; SIDE EFFECT; STOMACH CANCER; TREATMENT WITHDRAWAL; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I AS TOPIC; FEMALE; HUMANS; INCIDENCE; LEUKOCYTOSIS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; RISK; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 84864879098     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.325     Document Type: Article

References (13)

1. Cao Y, Tan A, Gao F, Liu L, Liao C, Mo Z (2009) A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis 24: 677-685
2. Cassier PA, Moreno Garcia V, Gomez-Roca C, Olmos D, Morales R, Del Conte G, Gallerani E, Brunetto A, Schoffski P, Marsoni S, Schellens JHM, Penel N, Voest EE, Evans TRJ, Plummer R, Wilson RH, Soria J, Tabernero J, Verweij J, Kaye SB, European Drug Development Network (2011) Doseresponse relationship in phase I clinical trials: a European Dose Drug Development Network (EDDN) collaboration study Proceedings of the American Society of Clinical Oncology. J Clin Oncol 29(Suppl): Abstr 3084
3. Falanga A, Levine MN, Consonni R, Gritti G, Delaini F, Oldani E, Julian JA, Barbui T (1998) The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: results from a randomized trial. Thromb Haemost 79: 23-27
4. Falanga A, Zacharski L (2005) Deep vein thrombosis in cancer: the scale of the problem and approaches to management. Ann Oncol 16: 696-701
5. Kabbinavar FF, Hurwitz HI, Yi J, Sarkar S, Rosen O (2009) Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 27: 199-205
6. Kahn SR, Ducruet T, Lamping DL, Arsenault L, Miron MJ, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Johri M, Shrier I (2005) Prospective evaluation of health-related quality of life in patients with deep venous thrombosis. Arch Intern Med 165: 1173-1178
7. Le Tourneau C, Razak AR, Gan HK, Pop S, Diéras V, Tresca P, Paoletti X (2011) Heterogeneity in the definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents: a review of the literature. Eur J Cancer 47: 1468-1475
8. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW, American Society of Clinical Oncology (2007) American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25: 5490-5505
9. Mandala M, Falanga A, Roila F (2010) Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann Oncol 19(Suppl 2): ii126-ii127
10. Mandala M, Clerici M, Corradino I, Vitalini C, Colombini S, Torri V, De Pascale A, Marsoni S (2012) Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'. Ann Oncol 23: 1416-1421
11. Maur M, Sessa C. Review: new biological insights in early clinical studies (2007) Hematol Oncol 25: 53-57
12. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300: 2277-2285
13. Vemulapalli S, Chintala L, Tsimberidou AM, Dhillon N, Lei X, Hong D, Kurzrock R (2009) Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a phase I clinic: the M. D. Anderson Cancer Center experience. Am J Hematol 84: 408-413